Skip to main content
. Author manuscript; available in PMC: 2018 May 4.
Published in final edited form as: Cancer Res. 2017 Dec 27;78(5):1127–1139. doi: 10.1158/0008-5472.CAN-17-1453

Figure 6. CPI-455 and DAC synergize to inhibit cell growth in 3 luminal breast cancer cell lines.

Figure 6

A&B. Viability dose response curves for 10 day exposure to CPI-203 or CPI-455 alone (A), or combination treatment with 3 days DAC (dosed at 1:150 ratio with KDM5i) followed by 10 days KDM5i (B) in MCF-7, T-47D, and EFM-19. C. Isobolograms generated from combination viability data in MCF-7, T-47D, and EFM-19 in (B). D. Annexin V binding in MCF-7 as determined by flow cytometry.